Ayala Pharmaceuticals (NASDAQ:ADXS) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research note released on Tuesday morning. The brokerage issued a sell rating on the stock.

Ayala Pharmaceuticals Price Performance

Shares of ADXS remained flat at $0.02 during trading hours on Tuesday. 53 shares of the stock were exchanged, compared to its average volume of 16,218. The stock has a 50-day simple moving average of $0.17 and a two-hundred day simple moving average of $0.46. Ayala Pharmaceuticals has a 12-month low of $0.00 and a 12-month high of $1.49. The company has a market capitalization of $852,660.00, a PE ratio of 0.00 and a beta of 1.56.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.